SHAREABLE PDF

CPAnet: the challenges of gaining evidence-based knowledge in chronic pulmonary aspergillosis

Rosanne Sprute [1,2,3], Helmut J.F. Salzer[4] and Danila Seidel[1,2,3]

[1]Dept of Internal Medicine, Faculty of Medicine and University of Cologne, Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany. [2]Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. [3]German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. [4]Dept of Internal Medicine/Pulmonology, Kepler University Hospital, Linz, Austria.

Corresponding author: Rosanne Sprute (rosanne.sprute@uk-koeln.de)

Shareable abstract (@ERSpublications)
Chronic pulmonary aspergillosis is a destructive fungal disease complicating many respiratory disorders. Evidence is scarce for clinical management decisions. CPAnet aims to improve patient care by collecting data in an international registry. https://bit.ly/3utUFH1

This single-page version can be shared freely online.

The term chronic pulmonary aspergillosis (CPA) is used to describe a wide range of severe chronic fungal infections mainly occurring in non-immunocompromised patients with pre-existing lung disease [1]. CPA is a long-term infection of the lung caused by moulds of the genus *Aspergillus*. In Europe, the majority of cases are caused by *A. fumigatus*. About three million people are diagnosed with CPA globally, mostly complicating tuberculosis, allergic bronchopulmonary aspergillosis (ABPA) or sarcoidosis [2].